Q3 EPS Estimates for Revolution Medicines Boosted by Wedbush

Revolution Medicines, Inc. (NASDAQ:RVMD) – Wedbush boosted their Q3 2025 earnings per share estimates for Revolution Medicines in a research note issued on Tuesday, June 24th. Wedbush analyst R. Driscoll now expects that the company will post earnings of $0.12 per share for the quarter, up from their prior forecast of ($1.21). Wedbush currently has a “Outperform” rating and a $73.00 price target on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for Revolution Medicines’ Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($3.41) EPS, FY2027 earnings at ($3.64) EPS, FY2028 earnings at ($3.10) EPS and FY2029 earnings at $1.97 EPS.

RVMD has been the subject of several other reports. Oppenheimer boosted their price target on Revolution Medicines from $70.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. HC Wainwright reissued a “buy” rating and set a $72.00 price objective (down previously from $73.00) on shares of Revolution Medicines in a research note on Wednesday, May 14th. Needham & Company LLC reissued a “buy” rating and set a $57.00 price objective on shares of Revolution Medicines in a research note on Tuesday. Guggenheim reissued a “buy” rating and set a $80.00 price objective on shares of Revolution Medicines in a research note on Wednesday. Finally, Stifel Nicolaus lowered their price objective on Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Twelve equities research analysts have rated the stock with a buy rating, According to MarketBeat, Revolution Medicines currently has an average rating of “Buy” and an average target price of $67.58.

Revolution Medicines Stock Performance

Shares of RVMD opened at $36.91 on Friday. Revolution Medicines has a one year low of $29.17 and a one year high of $62.40. The stock has a market capitalization of $6.88 billion, a price-to-earnings ratio of -9.23 and a beta of 1.10. The stock has a 50 day moving average price of $39.61 and a 200 day moving average price of $39.99.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same quarter in the prior year, the firm posted ($0.70) earnings per share.

Hedge Funds Weigh In On Revolution Medicines

Hedge funds have recently bought and sold shares of the stock. IFP Advisors Inc purchased a new position in Revolution Medicines during the fourth quarter worth $34,000. Banque Transatlantique SA acquired a new stake in shares of Revolution Medicines during the first quarter worth $42,000. Quarry LP acquired a new stake in shares of Revolution Medicines during the first quarter worth $50,000. Twin Tree Management LP acquired a new stake in shares of Revolution Medicines during the first quarter worth $58,000. Finally, Sterling Capital Management LLC boosted its holdings in shares of Revolution Medicines by 588.7% during the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company’s stock worth $86,000 after purchasing an additional 1,672 shares during the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.